

### **Publications resulting from research at SSTAR**

1. Jaffe, W.B., \*Bailey, G.L., Lohman, M., Riggs, P., McDonalds, L., Weiss, R.D. (2009). Methods of Recruiting Adolescents with Psychiatric and Substance Use Disorders for a Clinical Trial. *American Journal of Drug and Alcohol Abuse* 35(5):381-384. DOI: 10.1080/00952990903150860  
\*Equal contribution, shared first authorship
2. Ling W., Casadonte P., Bigelow G., Kampman K.M., Patkar A., Bailey G.L., Rosenthal R.N., Beebe K.L. (2010) Buprenorphine Implants for Treatment of Opioid Dependence: A Randomized Controlled Trial. *JAMA* 304(14):1576-83.
3. Riggs P.D., Winhusen T., Davies R.D., Leimberger J.D., Mikulich-Gilbertson S., Klein C., Macdonald M., Lohman M., Bailey G.L., Haynes L., Jaffee W.B., Hamilton N., Hodgkins C., Whitmore E., Trello-Rishel K., Tamm L., Acosta M.C., Royer-Malvestuto C., Subramaniam G., Fishman M., Holmes B.W., Kaye M.E., Vargo M.A., Woody G.E., Nunes E.V., Liu D. (2011). Randomized controlled trial of osmotic-release methylphenidate with cognitive behavioral therapy in adolescents with attention deficit/hyperactivity disorder and substance abuse disorders. *J Am Acad Child Adolesc Psychiatry*. 50(9):903-14. Epub 2011 Aug 4.
4. Campbell, A.N., Nunes, E.V., Miele, G.M., Matthews, A., Polksky, D., Ghitza, U.E., Turrigiano, E., Bailey, G.L., VanVeldhuisen, P., Chapdelaine, R., Froias, A., Stitzer, M.L., Carroll, K.M., Winhusen, T., Clingerman, S., Perez, L., McClure, E., Goldman, B., Crowell, A.R. (2012). Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. *Contemp Clin Trials*. 33(2):386-395.
5. Tamm, L., Trello-Rishel, K., Riggs, P., Nakonezny, P.A., Acosta, M., Bailey, G.L., Winhusen, T. (2012) Predictors of Treatment Response in Adolescents with Comorbid Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder. *J Subst Abuse Treat*, 44(2): 224-30.
6. Greenfield, S.F., Crisafulli, M.A., Kaufman, J.S., Freid, C.M., Bailey, G.L., Connery, H.S., Rapoza, M., Rodolico, M. (2013) Implementing substance abuse group therapy clinical trials in real-world settings: Challenges and Strategies for Participant Recruitment and Therapist Training in the Women's Recovery Group Study; *Am J on Addict*, 23(3):197-204.
7. Bailey, G.L., Herman, D.S., Stein, M.D. (2013). Perceived Relapse Risk and Willingness to Receive Medication among Opiate Dependent Persons in Inpatient Detoxification. *J Subst Abuse Treat*, 45(3):302-5.
8. Rosenthal, R.N., Ling, W., Casadonte, P., Voccie, F., Bailey, G.L., Kampman, K., Patkar, A., Chavouste, S., Beebe, K.L. (2013). Buprenorphine Implants for Treatment of Opioid Dependence: Randomized Comparison to Placebo and Sublingual Buprenorphine/Naloxone. *Addictions*, 108(12):2141-9.

9. Tamm, L., Trello-Richel, K., Riggs, P., Nakonezny, P.A., Acosta, M., Bailey, G.L., Winhusen, T. (2013). Predicting Treatment Response in Adolescents with ADHD Who Use Substances. *ADHD Report*, 21(6):1-5.
10. Stein, M.D., Anderson, B.J., Thurmond, P., Bailey, G.L. (2015). Comparing the life concerns of prescription opioid and heroin users. *Journal of Substance Abuse Treatment*, 48(1):43-48.
11. Najavits, L.M., Lung, J., Froias, A., Bailey, G.L., Paull, N.E. (2014). A Study of Multiple Behavioral Addictions in a Substance Abuse Sample. *Substance Use and Misuse*, 49(4):479-84.
12. Stein M.D., Bailey G.L., Thurmond P., Paull N. (2014). Looking for the Uninsured in Massachusetts? Check Opioid Dependent Persons Seeking Detoxification. *Drug and Alcohol Dependence*, 136:166-9.
13. Thurmond, P., Bailey, G.L., Stein, M.D. (2014). Willingness to Use HIV Preexposure Prophylaxis among Opiate Users. *AIDS and Behavior*, 18(9):1694-700.
14. Greenfield, S.F., Crisafulli, M.A., Kaufman, J.S., Freid, C.M., Bailey, G.L., Connery, H.S., Rapoza, M., Rodolico, J. (2014). Implementing substance abuse group therapy clinical trials in real-world settings: Challenges and strategies for participant recruitment and therapist training in the Women's Recovery Group Study. *American Journal on Addictions*, 23(3):197-204.
15. Greenfield, S.F., Kaufman, S.J., Bailey, G.L., Crisafulli, M.A., Freid, C., Connery, H., Rodolico, J., Wigderson, S., Rapoza, M., Fitzmaurice, G. (2014). The women's recovery group: Outcomes from a stage II trial. *Drug and Alcohol Dependence*, 140:e75.
16. Greenfield, S.F., Sugarman, D.E., Freid, C.M., Bailey, G.L., Crisafuli, M.A., Kaufman, J.S., Wigderson, S., Connery, H.S., Rodolico, J., Morgan-Lopez, A.A., Fitzmaurice, G.M. (2014). Group Therapy for Women with Substance Use Disorders: Results from the Women's Recovery Group. *Drug and Alcohol Dependence*, 142.
17. Campbell, A.N.C., Nunes, E.V., Pavlicova, M., Hatch-Mailette, M., Hu, M., Bailey, G.L., Sugarman, D.E., Miele, G.M., Rieckmann, T., Shores-Wilson, K., Turrigiano, E., Greenfield, S. (2014). Gender-based outcomes and acceptability of a computer-assisted psychosocial intervention for substance use disorders. *Journal of Substance Abuse Treatment*, 12/53.
18. Sugarman, D., Wigderson, S., Connery, S., Bailey, G.L., Fitzmaurice, G., Greenfield, S.F. (2015). Ancillary Treatment use in the stage II community-based women's recovery group therapy trial. *Drug and Alcohol Dependence*, 146:e111

19. Mitchell, S.G., Schwarts, R.P., Alvanzo, A.A.H., Weisman, M.S., Kyle, T.L., Turrigiano, E.M., Gibson, M.L., Perez, L., McClure, E.A., Clingerman, S., Froias, A., Shandera, D.R., Walker, R., Babcock, D.L., Bailey, G.L., Miele, G.M., Kunkel, L.E., Norton, M., Stitzer, M.L. (2015). The Use of Technology in Participant Tracking and Study Retention: Lessons Learned from a Clinical Trials Network Study. *Substance Abuse*.
20. Stein, M.D., Herman, D.S., Bailey, G.L., Straus, J., Anderson, B.J., Uebelaker, L.A., Weisberg, R.B. (2015). Chronic Pain and Depression Among Primary Care Patients Treated with Buprenorphine. *Journal of General Internal Medicine*, 30(7).
21. Stein, M.D., Anderson, B.J., Bailey, G.L. (2015). Preferences for aftercare among persons seeking short-term opioid detoxification. *Journal of Substance Abuse Treatment*, 59.
22. Uebelacker, L.A., Weisberg, R.B., Herman, D.S., Bailey, G.L., Pinkston, M.M., Stein, M.D. (2015). Chronic pain in HIV-infected patients: relationship to depression, substance use, and mental health and pain treatment. *Pain Medicine*, 16(10).
23. Stein, M.D., Risi, M.M., Flori, J.N., Conti, M.T., Anderson, B.J., Bailey, G.L. (2016). Gender Differences in the Life Concerns of Persons Seeking Alcohol Detoxification. *Journal of Substance Abuse Treatment*, 63, 34-38.
24. Stein, M.D., Caviness, C., Grimone, K., Audet, D., Anderson, B.J., Bailey, G.L. (2016). An Open Trial of Electronic Cigarettes for Smoking Cessation among Methadone-Maintained Smokers. *Nicotine & Tobacco Research*, 18(5)1157-62.
25. Uebelacker, L.A., Weisberg, R.B., Herman, D.S., Bailey, G.L., Pinkston, M.M., Garnaat, S., Stein, M.D. (2016). Pilot randomization trial of collaborative psychosocial treatment for chronic pain and depression in persons living with HIV/AIDS. *AIDS and Behavior*
26. Murphy, S., Campbell, A.N., Ghitza, U.E., Kyle, T.L., Bailey, G.L., Nunes, E.V., Polsky, D. (2016). Cost-Effectiveness of an Internet-Delivered Treatment for Substance Abuse: Data from a Multisite Randomized Controlled Trial. *Drug and Alcohol Dependence*.
27. Stein, M.D., Risi, M.M., Bailey, G.L., Anderson, B.J. (2016). Linkage of Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification. *Journal of Substance Abuse Treatment*, 64.
28. Uebelacker, L.A., Bailey, G.L., Herman, D.S., Anderson, B.J., Stein, M.D. (2016). Patients' beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no Medication Assisted Therapy following inpatient opioid detoxification. *Journal of Substance Abuse Treatment*, 66
29. Lee, J. Nunes, E.V., Novo, P., Bailey, G.L., Birgham, G.S., Cohen, A.J., Fishman, M., Ling, W., Lindblad, R., Shmueli-Blumberg, D. Stablein, D., May, J., Dagmar, S., Liu, D., Rotrosen, J. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study Design and Rationale:Contemporary

*Clinical Trials*, 08/2016.

30. Stein, M.D., Kanabar, M., Anderson, B.J., Lembke, A., Bailey, G.L. (2016). Reasons for benzodiazepine use among persons seeking opioid detoxification. *Journal of Substance Abuse Treatment*, 68.
31. Nunes, E.V., Lee, J.D., Sisti, D.A., Segal, A., Caplan, A.L., Fishman, M., Bailey, G., Brighman, G.S., Novo, P., Farkas, S., & Rotrosen, J. Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. *Contemporary Clinical Trials*, 09/2016.
32. Levesque, A., Campbell, A.N.C., Pavlicova, M., Hu, M., Walker, R., McClure, E.A., Ghitz, U.E., Bailey, G.L., Stitzer, M., Nunes, & E.V. Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. *Addictive Behaviors* 09/2016.
33. Stein, M.D., Flori, J.N., Blevins, C., Conti, M.T., Anderson, B.J., & Bailey, G.L. Brief report: Knowledge, past use, and willingness to start medication-assisted treatment among persons undergoing alcohol detoxification. *The American Journal on Addictions*, (2017) 26 (2), 118-121.
34. Dammerman, R., Bailey, G.L., Beebe, K.L., Chen, M., Rosenthal, R.N., et al. (2017). Long-term buprenorphine implants for treatment of opioid dependence: safety outcomes from two open-label extension trials. *Journal of Addictive Behaviors, Therapy & Rehabilitation*. 6(1). DOI: 10.4172/2324-9005.1000162
35. Stein, M. D., Anderson, B. J., Kenney, S. R., & Bailey, G. L. Beliefs about the Consequences of Using Benzodiazepines among Persons with Opioid Use Disorder, *Journal of Substance Abuse Treatment*. Jun: 77:67-71. doi: 10.1016/j.jsat.2017.03.002
36. Kenney, S. R., Anderson, B. J., Bailey, G. L., & Stein, M. D. The Relationship between Diversion-Related Attitudes and Sharing and Selling Buprenorphine, *Journal of Substance Abuse Treatment*. (2017) Jul;78:43-47.
37. Kenney, S. R., Bailey, G. L, Anderson, B. J., & Stein, M. D. Heroin Refusal Self-Efficacy and Preference for Medication-Assisted Treatment after Inpatient Detoxification, *Addictive Behaviors*. (2017) Oct;73:124-128.
38. Stein, M. D., Conti, M., Kenney, S. R., & Anderson, B. J., Flori, J. N., Risi, M. M., & Bailey, G. L. , Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder. *Drug and Alcohol Dependence*. 179: 325-329
39. Stein, M.D, Flori, J.N., Risi, M.M., Conti, M.T., Anderson, B.J., & Bailey, G.L. (2017). Overdose History Is Associated with Post-Detoxification Treatment Preference for Persons with Opioid Use Disorder. *Substance Abuse* 77:67-71.

40. Stein, M.D., Anderson B.J., Bailey, G.L. (2017). Broken Lives: Fights, Fractures, and Motor Vehicle Accidents among Heroin Users Entering Detoxification. *Drug Alcohol Dependence* 177, 194-198.
41. Stein, M.D., Santiago Rivera,O.J., Anderson, B. J., Bailey, G. L. (2017). Perceived Need for Depression Treatment among Persons Entering Inpatient Opioid Detoxification. *American Journal of Addiction*. 26 (4): 395-399.
42. Bozinoff, N., Andersen, B.J., Bailey, G.L., Stein, M.D. (2018). Correlates of stigma severity among persons seeking opioid detoxification, *Journal of Addiction Medicine*. 12(1), 19-23. DOI: 10.1097/ADM.0000000000000355
43. Kenney, S. R., Anderson, B. J., Bailey, G. L., & Stein, M. D. (2018). Factors associated with naloxone administration among opioid dependent persons, *Journal of Substance Abuse Treatment*, 84, 17-20. DOI: 10.1016/j.jsat.2017.10.008
44. Lee, J.D., Nunes, E.V., Jr., Novo, P., Bachrach, K., Bailey, G.L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C.C., King, J., Lindblad, R., Liu, D., Matthews, A.G., May, J., Peavy, K.M., Ross, S., Salazar, D., Schkolnik, P., Shmueli-Blumberg, D., Stablein, D., Subramaniam, G., Rotrosen, J. (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet*. 391:10118,308-318.
45. Lofwall, M.R., Walsh, S.L., Nunes, E.V., Bailey, G.L.; et.al. (2018) Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. *JAMA Intern Med*. 178(6), 764-773.
46. Kenney, S.R., Anderson, B., Bailey, G.L., Stein, M.D. (2018). Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. *Journal of Substance Abuse Treatment*, 94, 55-59. DOI: 10.1016/j.jsat.2018.08.011
47. Kenney, S.R., Anderson, B., Bailey, G.L., Stein, M.D. (2018). Drug use-related normative misperceptions and behaviors among persons seeking heroin withdrawal management. *Journal of Addiction Medicine*. DOI: 10.1097/ADM.0000000000000482
48. Kenney, S.R., Anderson, B., Bailey, G.L., Stein, M.D. (2019). Expectations about alcohol, cocaine, and benzodiazepine abstinence following inpatient heroin withdrawal management. *American Journal on Addictions*, 28(1), 36-42. DOI: 10.1111/ajad.12834
49. Yang, L.H., Grivel, M.M., Anderson, B., Bailey, G.L., Opler, M., Wong, L.Y., Stein, M.D. (2019). A new brief opioid stigma scale to assess perceived public attitudes and internalized stigma: Evidence for construct validity. *Journal of Substance Abuse Treatment*, 99, 44-51. DOI: 10.1016/j.jsat.2019.01.005
50. Stein, M.D., Conti, M.T., Herman, D.S., Anderson, B.J., Bailey, G.L., Van Noppen, D., Abrantes, A.M. (2019). Worries about Discontinuing Buprenorphine Treatment: Scale

Development and Clinical Correlates. *American Journal on Addictions*, 28 (4), 270-276.  
DOI: [10.1111/ajad.12884](https://doi.org/10.1111/ajad.12884)

51. Frost, M., Bailey, G.L., Lintzeries, N., Strang, J., Dunlop, A., Nunes, E.V., Billeskov Jansen, J., Chemnitz Frey, L., Weber, B., Haber, P., Oosman, S., Kim, S., Tiberb, F. (2019). Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. *Addiction*, 114 (8), 1416-1426. DOI: [10.1111/add.14636](https://doi.org/10.1111/add.14636)
  52. Stein, M.D., Kenney, S.R., Anderson, B.J., Bailey, G.L. (2019). Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use. *Journal of Substance Abuse Treatment*, 104, 144-147. DOI: [10.1016/j.jsat.2019.07.006](https://doi.org/10.1016/j.jsat.2019.07.006)
- Stein, M.D., Herman, D., Conti, M.T., Anderson, B.A., Bailey, G.L. (2019). Initiating buprenorphine treatment for opioid use disorder during short term inpatient “detoxification”: